🎉 M&A multiples are live!
Check it out!

Faron Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Faron Pharmaceuticals and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Faron Pharmaceuticals Overview

About Faron Pharmaceuticals

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested for the prevention of complications that arise from cytokine release syndrome, or hyperinflammatory conditions.


Founded

2006

HQ

United Kingdom of Great Britain and Northern Ireland
Employees

25

Website

faron.com

Financials

LTM Revenue $3.1M

LTM EBITDA -$15.1M

EV

$341M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Faron Pharmaceuticals Financials

Faron Pharmaceuticals has a last 12-month revenue of $3.1M and a last 12-month EBITDA of -$15.1M.

In the most recent fiscal year, Faron Pharmaceuticals achieved revenue of n/a and an EBITDA of -$27.9M.

Faron Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Faron Pharmaceuticals valuation multiples based on analyst estimates

Faron Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$36.6M -$27.9M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$37.0M -$39.8M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt $7.7M $7.8M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Faron Pharmaceuticals Stock Performance

As of April 15, 2025, Faron Pharmaceuticals's stock price is GBP 2 (or $3).

Faron Pharmaceuticals has current market cap of GBP 262M (or $338M), and EV of GBP 265M (or $341M).

See Faron Pharmaceuticals trading valuation data

Faron Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$341M $338M XXX XXX XXX XXX $-0.28

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Faron Pharmaceuticals Valuation Multiples

As of April 15, 2025, Faron Pharmaceuticals has market cap of $338M and EV of $341M.

Faron Pharmaceuticals's trades at 90.4x LTM EV/Revenue multiple, and -18.9x LTM EBITDA.

Analysts estimate Faron Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Faron Pharmaceuticals and 10K+ public comps

Faron Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $341M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -12.2x XXX XXX XXX
P/E -10.1x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -11.4x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Faron Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Faron Pharmaceuticals Valuation Multiples

Faron Pharmaceuticals's NTM/LTM revenue growth is 148%

Faron Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.0M for the same period.

Over next 12 months, Faron Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Faron Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Faron Pharmaceuticals and other 10K+ public comps

Faron Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -24% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.0M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Faron Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Faron Pharmaceuticals M&A and Investment Activity

Faron Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Faron Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Faron Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Faron Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Faron Pharmaceuticals

When was Faron Pharmaceuticals founded? Faron Pharmaceuticals was founded in 2006.
Where is Faron Pharmaceuticals headquartered? Faron Pharmaceuticals is headquartered in United Kingdom of Great Britain and Northern Ireland.
How many employees does Faron Pharmaceuticals have? As of today, Faron Pharmaceuticals has 25 employees.
Is Faron Pharmaceuticals publicy listed? Yes, Faron Pharmaceuticals is a public company listed on LON.
What is the stock symbol of Faron Pharmaceuticals? Faron Pharmaceuticals trades under FARN ticker.
When did Faron Pharmaceuticals go public? Faron Pharmaceuticals went public in 2015.
Who are competitors of Faron Pharmaceuticals? Similar companies to Faron Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Faron Pharmaceuticals? Faron Pharmaceuticals's current market cap is $338M
What is the current revenue of Faron Pharmaceuticals? Faron Pharmaceuticals's last 12-month revenue is $3.1M.
What is the current EBITDA of Faron Pharmaceuticals? Faron Pharmaceuticals's last 12-month EBITDA is -$15.1M.
What is the current EV/Revenue multiple of Faron Pharmaceuticals? Current revenue multiple of Faron Pharmaceuticals is 90.4x.
What is the current EV/EBITDA multiple of Faron Pharmaceuticals? Current EBITDA multiple of Faron Pharmaceuticals is -18.9x.
Is Faron Pharmaceuticals profitable? Yes, Faron Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.